BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 15514375)

  • 1. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
    Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
    Socinski MA; Rosenman JG; Halle J; Schell MJ; Lin Y; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
    Cancer; 2001 Sep; 92(5):1213-23. PubMed ID: 11571735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
    Stinchcombe TE; Lee CB; Moore DT; Rivera MP; Halle J; Limentani S; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Nov; 3(11):1279-85. PubMed ID: 18978563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
    J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
    Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
    Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J
    J Clin Oncol; 2001 Jan; 19(2):442-7. PubMed ID: 11208837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
    Lee CB; Stinchcombe TE; Moore DT; Morris DE; Hayes DN; Halle J; Rosenman JG; Rivera MP; Socinski MA
    J Thorac Oncol; 2009 Jan; 4(1):74-9. PubMed ID: 19096310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.